Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it will be filing for marketing approval of Fexapotide Triflutate for benign prostate hyperplasia (BPH) before the end of the summer, on or before 15 September 2021.
CEO Dr. Paul Averback said, "The Company will file on or before September 15. We hope but cannot be certain that the date may be before September. Company management will communicate updates where appropriate."
https://finance.yahoo.com/news/nymox-announces-date-fexapotide-filing-173000788.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.